Gilead Sciences Inc

Gilead says additional data on remdesivir shows improved clinical recovery

Findings from an analysis of its late-stage study showed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percent of patients receiving standard of care, the company said.

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.

Gilead's remdesivir shows promise in COVID-19 study on monkeys

Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies is being closely watched as nations look for a treatment for the disease, which has infected more than 7 million people and killed over 400,000.

Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions

Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better.

Gilead says remdesivir helped moderate COVID-19 patients improve

At Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, Gilead said.

Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

Preliminary results from a U.S. government trial showing that patients given remdesivir recovered 31% faster than those given a placebo, were hailed by Dr Anthony Fauci as "highly significant."

In Pics | All you need to know about Gilead's experimental antiviral drug Remdesivir

The drug is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19

Natco up 4% on settlement with US cos for antiviral drug

Natco and Alvogen have partnered on the first abbreviated new drug application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate), 30 mg, 45 mg and 75 mg.